The mechanism we're betting on.
HTN + atherosclerosis combined protocol — 28 compounds, 10 mechanisms M1–M10, 5-phase 24-week design with CAC (coronary artery calcium) primary endpoint. Includes the novel five-layer reversal hypothesis where Layer 3 (macrophage mineral resorption) is genuinely novel. PLAQUE-REVERSE trial design. 2nd provisional patent filed. The full mechanism map — including compound list, dose escalation, pre-specified biomarker thresholds, and the cross-walk modifiers used when re-fitting blends from related indications — is part of the gated methodology pack.Gated
What the rest of the world is doing.
Numbers below are surfaced by Atlas Bio's ClinicalTrials.gov and PubMed RWE pipelines, run against the Atherosclerosis & Reversal indication. Counts are industry-wide trials registered on ClinicalTrials.gov, not Atlas Bio studies. Methodology →
- Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. · PMID 9892520 · Vascular medicine (London, England) · 1998
- Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: · PMID 37932236 · Diabetes, obesity & metabolism · 2024
- Nattokinase atherothrombotic prevention study: A randomized controlled trial. · PMID 33843667 · Clinical hemorheology and microcirculation · 2021
Locked before readout.
Predictions for this study are SHA-256 locked before any readout. Pre-registration covers target engagement, primary endpoint, secondary endpoints, and the falsification criterion. The hash, prediction wording, and timestamp are available to verified clinicians and indication researchers on request.Gated
Same stack, every indication.
- M2 · Pre-Registration — SHA-256 locking before readout.
- M1 · IBC Reasoning — 19-agent audit (11 core + 8 reasoning nodes).
- M3 · Cross-Trial Validation — mechanism-anchored bridging across indications.
- M4 · RWE Pipelines — ClinicalTrials.gov, PubMed, FDA, EDGAR feeds (the source of the numbers above).
Want the full Atherosclerosis & Reversal protocol?
The abstract above is open. Compound lists, dose escalations, SHA-256-locked prediction documents, agent-network reasoning chains, and trial design specifics are available to verified clinicians, indication researchers, and sponsors under MNDA. Contact management to begin the access request.
Contact management →